Evaluation of the Relationship Between Factor IX Inhibitor in Hemophilia B Patients and Different Types of Therapy in the North-eastern Part of Iran

Hassan Mansouri Torghabeh MSc¹, Aliakbar Pourfathollah PhD², Mahmoud Mahmoudian Shoushtari PhD³

¹. Immunology Research Center, Ghaem Hospital, Mashhad, Iran.
². Experimental Hematology Group, Medical Sciences School, Tarbiat Modares University, Tehran, Iran.
³. Iranian Blood Transfusion Organization, Tehran, Iran.

Corresponding Author: Hassan Mansouri Torghabeh, Immunology Research Centre, Ghaem Hospital, Mashhad, Iran. P.O.Box: 91766-99199, Tel: +98(511)8012761, Fax: +98(512) 4225157, E-mail: Mansouritorghabe@mums.ac.ir

Abstract

Background: Hemophilia B is a bleeding disorder with a recessive X-linked inheritance pattern, in which the infected individuals have low levels of factor IX in their plasma. Affected individuals may have bleeding episodes after trauma or spontaneously considering the plasma level of factor IX. In order to prevent these episodes and to control bleeding, they should use coagulation factor concentrates that may be associated with the formation of inhibitors.

Methods: This study was conducted in the northeast of Iran in 2006. Among 48 individuals who agreed to participate in our survey, 3 individuals (6.25%) had used FFP, 38 s (79.16%) factor IX concentrate and 7 (14.58 both FFP and factor IX concentrate in the 6 months prior to the study. Of them, three participants (6.3%) had factor IX inhibitor which was assayed using Bethesda method.

Results: Three hemophilia B (6.3%) patients had factor IX inhibitor, but no correlation was found between the existence of the inhibitor and the type of coagulation therapy.

Conclusion: Our findings did not show any correlation between factor IX inhibitor and type of coagulation therapy used in the 6 month period (p=0.65). None of the hemophiliacs had used coagulation factor as a prophylaxis regimen and most of them (83.33%) had injected coagulation factor on demand.

Keywords: hemophilia B, coagulation factor concentrates, inhibitor of factor IX.

Brief Report

Hemophilia B is a lifetime hemorrhagic disorder (1). The gene encoding coagulation factor IX is located on chromosome X. This bleeding disorder is inherited in a recessive X-linked pattern.²,³ It is classified into severe, moderate, and mild according to the level of factor IX in plasma. Although hemorrhage in individuals with the mild form occurs after trauma or surgery, individuals with the severe form of the disease may experience various bleeding episodes spontaneously.⁴,⁵

To control bleeding episodes in these individuals and also for prophylaxis, appropriate volumes of factor IX concentrates (FIXC) should be injected to them.⁶,⁷ In developing countries where fresh frozen plasma (FFP) is cheap, it is infused to affected individuals when there is no access to FIXC.⁸,⁹

Except for concerns about virus-infected products,¹⁰ a new concern that has emerged is the formation of factor IX inhibitor in hemophiliacs. Individuals with factor IX inhibitor have more severe haemorrhagic episodes and control of bleeding is difficult in them.¹¹ Our main aim was to address the relationship between factor IX inhibitor antibody and administration of various types of coagulation factors.

Forty eight cases with hemophilia B from various cities of North-eastern Iran agreed to
participate in this survey in 2006. These participants were invited to Ghaem hospital to fill out a questionnaire and give blood samples. Their mean age was 21.35 ± 11.8 SD years of age ranging from 4 to 53. They were 22 individuals (48%) with severe, 18 individuals (37.7%) with moderate and 8 individuals (16.5%) with mild haemophilia B.

After mixing blood samples with 3.2gr/dl (0.109 M) trisodium citrate at a ratio of 1:9, blood samples were centrifuged at 2000 rpm for 15 minutes to obtain poor platelet plasma (PPP). Two tests, activated partial thromboplastine time (APTT) mix and Bethesda, were done on PPP according to the procedures described in detail in our previous article.12

Our results showed that only 3 individuals (6.25%) had used FFP but none of them had factor IX inhibitor, only 38 individuals (79.16%) had used FIXC with 3 of them having factor IX inhibitor. Finally, 7 individuals (14.58%) had used both FIXC and FFP but none of them had the inhibitor. The status of coagulation therapy in a period of 6 months was studied. Only 38 individuals (79.1%) had used FIXC and others did not have access to FIXC in bleeding episodes.

Three hemophilia B patients (6.3%) had the factor IX inhibitor and their inhibitor titers were 0.88, 1.48 and 1.8 Bethesda Unit (B.U.), respectively.

Chi-square test was done to detect any relationship between the existence of the inhibitor and type of coagulation therapy, but no relationship was found (p=0.656).

It revealed that 1 individual (2.08%) had used coagulation factor every 3 days, 4 individuals (8.33%) had used coagulation factor every other week, 2 individuals (4.16%) every month, 1 individual (2.08%) every 2 months, and 40 (83.33%) had used it only on demand.

### Discussion

Although, Modern control of hemophilia was introduced in 1970s with the introduction of coagulation factor concentrates,13 it seems that preparation of coagulation factor concentrates is one of the many problems in hemophiliacs care in developing countries.8 In the present survey, only 3 individuals (6.25%) had used FFP in the 6 months period, 38 individuals (79.1%) had used FIXC, 7 individuals (14.5%) had used both FFP and FIXC. This shows that individuals with hemophilia B do not have enough access to coagulation factor concentrates or distribution of coagulation factors among hemophiliacs is not sufficient and more attention should be paid in this regard.

The frequency of factor IX inhibitor has been reported in various ethnic groups it is similar to our results.14-18 Another issue is the relationship between factor IX inhibitor and FIXC administration that has been reported in the early studies.19,20 Although this relationship has been reported in some coagulation factor products,21 more important factors such as Human Leukocyte Antigens (HLA)22-24 and genetic abnormalities in the factor IX gene are recently argued.25-27 All 3 participants with haemophilia B who had inhibitor

<table>
<thead>
<tr>
<th>Type of coagulation therapy</th>
<th>Result for inhibitor</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
<td>Positive</td>
</tr>
<tr>
<td>FFP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Count</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>%Within treatment</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>FIX Concentrate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Count</td>
<td>35</td>
<td>3</td>
</tr>
<tr>
<td>% Within treatment</td>
<td>92.1%</td>
<td>7.9%</td>
</tr>
<tr>
<td>FFP+FIX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Count</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>% Within treatment</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Total</td>
<td>45</td>
<td>3</td>
</tr>
<tr>
<td>% Within treatment</td>
<td>93.8%</td>
<td>6.3%</td>
</tr>
</tbody>
</table>

FFP: fresh frozen plasma; FIX: factor X.
belonged to the group which had used FIXC but
our findings did not reveal any relationship
between the type of coagulation factor
concentrates and the existence of factor IX
inhibitor. This may be due to the number of our
cases or the pattern of coagulation factor
administration, because none of our individuals
had used one single type of coagulation factor
products in their life. Also, the frequency of
coagulation therapy is an important factor.

Although nowadays prophylaxis is used in
hemophilia B patients every 3 days to prevent
hemorrhagic episodes, most individuals in our
study had used coagulation therapy only after a
hemorrhagic event had occurred. This pattern of
coaugulation therapy supports inadequate
coagulation therapy in these individuals. In our
region, no one had used prophylaxis regimen to
prevent bleeding events.

Acknowledgment
The authors wish to thank Iranian Blood
Transfusion Organization for the grant, and
haemophilia B patients who participated in this
study.

References
1. Mannucci PM, Tuddenham E. The hemophilia from
1773-9.
2. Miners A.H., Sabin C.A., Tolley K.H., Batlorn S.,
Moatawal L Assessing the relation between productivity
levels and severity of hemophilia. Haemophilia; 2001. 7:
459-63.
3. Liras A. Gene therapy for hemophilia: The end of a
Royal pathology in the third millennium? Hemophilia.
2001. 7: 441-5
4. Roberts HR, Jenes MR. Hemophilia and related
5. Rizza C, Lowe G. Hemophilia and other inherited
6. Rodriguez MEC. Effects of hemophilia on
7. Yee TT, Beeton K, Griffioen A. Experience of
prophylaxis treatment in children with severe
hemophilia. Haemophilia; 2002. 8: 76-82.
8. Sirvastava A. Choice of factor concentrates for
hemophilia: a developing world perspective.
9. Mannucci PM, Giangrande PL. Choice of
replacement therapy for hemophilia: recombinant
10. Minor PD. Are recombinant products really
11. Fischer K, Van Der Bom JG, Mauser-Bunschoten
EP, Roosendall G. Changes in treatment strategies for
severe hemophilia over the last 3 decades. Hemophilia;
2001. 7: 446-52.
12. Mansouri Torghabeh H, Pourfathollah AA,
Mahmoodian Shooshtari M, Rezaie Yazdi Z. First survey
of factor IX inhibitor in North-eastern Iran: Med J. Islam
13. Stachnik JM, Gabay MP. Continuous infusion of
36: 882-91.
L. Incidence of development of factor VIII and factor IX
15. Mc Millan CW, Shapiro SS, Whitehurst D, Hoyer
LV, Rao AV and Lazerson J. The nature history of
factor VIII: C inhibitor in individuals with hemophilia A:
Oldeng ECD. A retrospective of the frequency and
severity of allergic reactions reported with factor IX
17. Yoshikatsu S, Midori S, Masakoni Y, Seiki K, Namer
PK, Petrini K et al. Measurement of anti factor IX IgG
subclasses in hemophilia B individuals who developed
inhibitors with episodes of allergic reactions to factor IX
18. Kumar SA, Kern MA, Blanchette V. Factor VIII
inhibitors in mild hemophiliacs following continues
infusion of recombinant factor VIII. Is there a casual
19. Ehrenforth S, Kreuz W, Scharre I, Linde R,
Mollison BC. Incidence of development of factor VIII
20. Jeame M. Inhibitors in young boys with
21. Tuddenham ECG. Molecular biological aspects of
22. Tiwari J, Terasaki PI. HLA and disease association.
23. Oldenburg J, Brackman HH, Schwaab R. Risk
factor for inhibitor developing in hemophilia.